Pharma's Market
SPECIAL REPORT
MOST SHARED
- We're Not Greece: Italian Prime Minister Monti
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- To Play Senate Cybersecurity Bill, Cramer Likes Fortinet Stock
- Greek Cabinet Approves EU, IMF Bailout Bill
- Special Feature: Wall Street History - How Wall Street Got Its Name
- How to Trade the Turmoil in Greece
- Private Homebuilders: Dead Men Walking
- Why Cramer Likes Select Comfort Over Tempur-pedic Stock
- Cramer: 10 Earnings to Watch Next Week
- Lightning Round: Trina Solar, Zoltek, Affymax and More
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- Greek Cabinet Approves EU, IMF Bailout Bill
- We're Not Greece: Italian Prime Minister Monti
- Private Homebuilders in the US: Dead Men Walking
- Dividend Payout Could Hit Record Amount This Year
- With Investors So Bullish, Stock Pullback Must Be Ahead
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- New York Fashion Week Fall 2012
- NetNet: Why Saving Greece Could Destroy the World
- My Funny Valentine: When Love and the Fed Collide
RSS FEED
Dendreon's Provenge Backers Want Action: Marching On FDA
Text Size 
Reporter
 |
AP |
Sept. 5th-8th the Department of Defense's Prostate Cancer Research Program will hold its conference called the 2007 Innovative Minds in Prostate Cancer Today, or IMPaCT for short, in Atlanta.
On Sept. 27th and 28th the National Prostate Cancer Coalition will hold its annual Advocacy Day (actually, it's two days) in Washington, DC.
And on September 18th Provenge proponents announced today that they will be holding "A Right To Live Day" at Food and Drug Administration headquarters in Rockville, MD. On its Web site, www.arighttolive.com, the organization says it's an "all-volunteer advocacy group", but doesn't divulge whether its base is made up of patients, their advocates, and/or investors. Scott Riccio, the founding member of Right to Live, told me over the phone the group is made up of all three stakeholders. He says he does not own DNDN shares.
The group will be protesting the FDA's controversial delay in the potential approval of Dendreon's [DNDN
Loading...
()
] Provenge. Riccio is quoted in a press release saying, "It has become very clear over the past few years that the FDA has instituted a decelerated approval process for cancer therapies....There has never been such an incredible, irrational and unjustifiable denial of rights of dying patients by such a dysfunctional agency."
This protest follows two small demonstrations in Washington and in Chicago at the American Society of Clinical Oncology meeting last June.
The FDA says it makes decisions about whether to approve or reject drugs based solely on the scientific evidence--the clinical trial data. In the case of Provenge, the agency has asked for the results of an ongoing, larger study aimed directly at determining if the drugs extends patients' lives and, if so, by how much. The preliminary data are expected, at the earliest, the middle of next year.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
